IN2012DN04908A - - Google Patents

Download PDF

Info

Publication number
IN2012DN04908A
IN2012DN04908A IN4908DEN2012A IN2012DN04908A IN 2012DN04908 A IN2012DN04908 A IN 2012DN04908A IN 4908DEN2012 A IN4908DEN2012 A IN 4908DEN2012A IN 2012DN04908 A IN2012DN04908 A IN 2012DN04908A
Authority
IN
India
Prior art keywords
antibody
disclosed
antibodies
expressing cells
drug conjugates
Prior art date
Application number
Other languages
English (en)
Inventor
Michel Pierres
Eric Vivier
Myriam Baratin
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43827827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN04908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of IN2012DN04908A publication Critical patent/IN2012DN04908A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN4908DEN2012 2009-12-09 2010-12-08 IN2012DN04908A (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28501809P 2009-12-09 2009-12-09
PCT/IB2010/003411 WO2011070443A1 (en) 2009-12-09 2010-12-08 Monoclonal antibodies that bind b7h6 and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN04908A true IN2012DN04908A (pl) 2015-09-25

Family

ID=43827827

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4908DEN2012 IN2012DN04908A (pl) 2009-12-09 2010-12-08

Country Status (18)

Country Link
US (2) US8822652B2 (pl)
EP (1) EP2510011B2 (pl)
JP (2) JP2013513380A (pl)
CN (2) CN104926942B (pl)
BR (1) BR112012013975B8 (pl)
CA (1) CA2783740C (pl)
DK (1) DK2510011T3 (pl)
EA (1) EA024629B1 (pl)
ES (1) ES2523472T3 (pl)
HR (1) HRP20141170T1 (pl)
IN (1) IN2012DN04908A (pl)
MX (1) MX2012006443A (pl)
PL (1) PL2510011T3 (pl)
PT (1) PT2510011E (pl)
RS (1) RS53667B1 (pl)
SI (1) SI2510011T1 (pl)
SM (1) SMT201400184B (pl)
WO (1) WO2011070443A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
WO2011070443A1 (en) 2009-12-09 2011-06-16 Institut National De La Sante Et De La Recherche Medicale Monoclonal antibodies that bind b7h6 and uses thereof
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
CN103797032B (zh) 2011-09-13 2016-10-12 德国癌症研究中心 抗b7-h6多肽的b7-h6治疗性活性单克隆抗体
WO2013169691A1 (en) 2012-05-07 2013-11-14 Trustees Of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
EP2711707A1 (en) 2012-09-21 2014-03-26 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to chemotherapy
WO2014044799A1 (en) * 2012-09-21 2014-03-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for the diagnosing of inflammatory conditions involving detecting, identifying or assaying for soluble b7-h6 polypeptides
US11034767B2 (en) * 2016-04-15 2021-06-15 Trustees Of Dartmouth College High affinity B7-H6 antibodies and antibody fragments
EP3469001A4 (en) * 2016-06-09 2020-05-06 Seattle Genetics, Inc. COMBINATIONS OF PBD-BASED ANTIBODY CONJUGATES WITH FLT3 INHIBITORS
CN111788226A (zh) * 2017-11-16 2020-10-16 抗原生成有限责任公司 溶酶体诱导的免疫原性细胞死亡的系统和方法
IL294714A (en) * 2020-01-17 2022-09-01 Beigene Ltd Anti-nkp30 antibodies and methods of using them
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
CN114395043B (zh) * 2021-12-07 2023-07-11 合肥天港免疫药物有限公司 Ncr3lg1抗体及其应用
CN114395044B (zh) * 2021-12-07 2023-12-29 合肥天港免疫药物有限公司 重组抗体及其应用
CN114395045B (zh) * 2021-12-07 2023-06-09 合肥天港免疫药物有限公司 B7h6抗体及其应用
CN114395047B (zh) * 2021-12-07 2023-11-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
WO2024005422A1 (ko) * 2022-06-29 2024-01-04 고려대학교 산학협력단 Nkp30 결합력이 향상된 b7-h6 변이체
WO2024104777A1 (en) * 2022-11-16 2024-05-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts T cell-nk cell interaction inhibitors for use in disease treatment

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4883662A (en) 1984-04-10 1989-11-28 Clinical Biotechnologies, Inc. Method of increasing natural killer cell population of cancer patients
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
FI102355B (fi) 1988-02-11 1998-11-30 Squibb Bristol Myers Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5082833A (en) 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
DK0871490T3 (da) 1995-12-22 2003-07-07 Bristol Myers Squibb Co Forgrenede hydrazonlinkere
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US6239104B1 (en) 1997-02-25 2001-05-29 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
AU2769101A (en) * 2000-01-07 2001-07-24 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
PT1545613E (pt) 2002-07-31 2011-09-27 Seattle Genetics Inc Conjugados de auristatina e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infecciosa
AU2003258714A1 (en) * 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
WO2006124668A1 (en) * 2005-05-12 2006-11-23 Zymogenetics, Inc. Methods of using pnkp30, a member of the b7 family, to modulate the immune system
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
JP5496897B2 (ja) * 2007-10-04 2014-05-21 ザイモジェネティクス， インコーポレイテッド Ｂ７ファミリーメンバーのｚＢ７Ｈ６ならびに関連する組成物および方法
WO2011070443A1 (en) 2009-12-09 2011-06-16 Institut National De La Sante Et De La Recherche Medicale Monoclonal antibodies that bind b7h6 and uses thereof

Also Published As

Publication number Publication date
CN102741290A (zh) 2012-10-17
CN104926942A (zh) 2015-09-23
EA201270654A1 (ru) 2013-02-28
BR112012013975B1 (pt) 2021-01-12
CN104926942B (zh) 2018-09-14
CA2783740A1 (en) 2011-06-16
PL2510011T3 (pl) 2015-02-27
DK2510011T3 (en) 2014-12-01
EP2510011B1 (en) 2014-09-17
US8822652B2 (en) 2014-09-02
US20130004432A1 (en) 2013-01-03
JP2013513380A (ja) 2013-04-22
US20150056214A1 (en) 2015-02-26
PT2510011E (pt) 2014-12-12
SMT201400184B (it) 2015-01-15
ES2523472T3 (es) 2014-11-26
HRP20141170T1 (hr) 2015-01-30
MX2012006443A (es) 2012-06-28
CA2783740C (en) 2020-03-10
EA024629B1 (ru) 2016-10-31
BR112012013975B8 (pt) 2021-05-25
EP2510011B2 (en) 2021-03-31
JP2017031147A (ja) 2017-02-09
US9663577B2 (en) 2017-05-30
CN102741290B (zh) 2015-04-22
RS53667B1 (en) 2015-04-30
BR112012013975A2 (pt) 2017-01-10
SI2510011T1 (sl) 2014-12-31
JP6212181B2 (ja) 2017-10-11
EP2510011A1 (en) 2012-10-17
WO2011070443A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
IN2012DN04908A (pl)
IL287292A (en) and fusion antibody-drug-cd79b engineered antibodies cysteine-
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
EA201070463A1 (ru) Комбинированная терапия с использованием конъюгатов антитело-лекарственное средство
NO20084356L (no) Anti TAT226-antistoffer og immunokonjugater
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
NZ595574A (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
MY170719A (en) Antibody-drug conjugates
NZ602220A (en) Antibodies with ph dependent antigen binding
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
SG170091A1 (en) Anti-5t4 antibodies and uses thereof
HK1162119A1 (en) Animal models and therapeutic molecules
UA107574C2 (ru) Гуманизированное антитело, специфическое к протофибрилярной формы бета-амилоидного пептида
WO2009046407A3 (en) B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
MY197840A (en) Cross-linkers and their uses
IL214983A0 (en) Antibody drug conjugated that bind monomethyl auristatin e (mmae), compositions comprisimg the same and uses thereof
IL218740A0 (en) New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
EP2244729A4 (en) ANTIBODIES OBTAINED BY CYSTEINE FOR THE SPECIFIC CONJUGATION OF A SITE
AU2011343161A8 (en) Human anti-SOD1 antibodies
MX2012009564A (es) ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
NZ616382A (en) Antibodies specific to cadherin-17
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.
EP2519542A4 (en) ANTI-CDH3 ANTIBODY AND ITS USE
CY1116022T1 (el) Μονοκλωνικα αντισωματα τα οποια δεσμευουν ton β7η6 και χρησεις αυτων
UA99211C2 (en) Nanocapsules with functions of nanorobot